文献速递临床试验与 GCP基础与转化研究

英夫利西单抗诱导期治疗药物监测与标准治疗对慢性免疫介导炎症性疾病疾病缓解的影响:一项随机临床试验

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该随机开放标签试验纳入411例起始英夫利西单抗治疗的慢性免疫介导炎症性疾病成人患者,比较主动治疗药物监测与标准治疗。

要点

  • 主动TDM组第30周临床缓解率50.5%,标准治疗组53.0%,差异无统计学意义。
  • 两组不良事件发生率相似(68% vs 70%)。
  • 不推荐在英夫利西单抗诱导期常规开展TDM以提升疾病缓解率。

核心结论

  • 在起始英夫利西单抗治疗的免疫介导炎症性疾病患者中,主动TDM相比标准治疗未显著改善30周临床缓解率。
  • 研究结果不支持在英夫利西单抗诱导期常规使用TDM来改善疾病缓解率。

研究设计与样本

  • 随机、平行组、开放标签临床试验,在挪威21家医院开展。
  • 纳入411例起始英夫利西单抗治疗的成人患者(类风湿关节炎、脊柱关节炎、银屑病关节炎、溃疡性结肠炎、克罗恩病或银屑病)。
  • 患者1:1随机分为主动TDM组(n=207)和标准治疗组(n=204)。

主要发现

  • 第30周临床缓解率:TDM组100/198(50.5%),标准治疗组106/200(53.0%)。
  • 不良事件:TDM组135例(68%),标准治疗组139例(70%)。

关键数值与推荐

  • 主要终点为第30周临床缓解。
  • 主动TDM组根据计划性血清药物浓度和抗药抗体监测调整剂量和间隔。
  • 标准治疗组不进行药物和抗体水平监测。

临床怎么用

  • 对于起始英夫利西单抗诱导治疗的免疫介导炎症性疾病患者,不应常规进行主动TDM以改善缓解率。
  • 临床决策仍需结合患者个体情况和疾病活动度。

局限性

  • 开放标签设计可能引入偏倚。
  • 随访至第30周,长期结果未报告。
  • 研究在挪威进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and other biological drugs. However, whether proactive TDM improves clinical outcomes when implemented at the time of drug initiation, compared with standard therapy, remains unclear. OBJECTIVE: To assess whether TDM during initiation of infliximab therapy improves treatment efficacy compared with standard infliximab therapy without TDM. DESIGN, SETTING, AND PARTICIPANTS: Randomized, parallel-group, open-label clinical trial of 411 adults with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis initiating infliximab therapy in 21 hospitals in Norway. Patients were recruited from March 1, 2017, to January 10, 2019. Final follow-up occurred on November 5, 2019. INTERVENTIONS: Patients were randomized 1:1 to receive proactive TDM with dose and interval adjustments based on scheduled monitoring of serum drug levels and antidrug antibodies (TDM group; n = 207) or standard infliximab therapy without drug and antibody level monitoring (standard therapy group; n = 204). MAIN OUTCOMES AND MEASURES: The primary end point was clinical remission at week 30. RESULTS: Among 411 randomized patients (mean age, 44.7 [SD, 14.9] years; 209 women [51%]), 398 (198 in the TDM group and 200 in the standard therapy group) received their randomized intervention and were included in the full analysis set. Clinical remission at week 30 was achieved in 100 (50.5%) of 198 and 106 (53.0%) of 200 patients in the TDM and standard therapy groups, respectively (adjusted difference, 1.5%; 95% CI, -8.2% to 11.1%; P = .78). Adverse events were reported in 135 patients (68%) and 139 patients (70%) in the TDM and standard therapy groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with immune-mediated inflammatory diseases initiating treatment with infliximab, proactive therapeutic drug monitoring, compared with standard therapy, did not significantly improve clinical remission rates over 30 weeks. These findings do not support routine use of therapeutic drug monitoring during infliximab induction for improving disease remission rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03074656.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Syversen SW, Goll GL, Jørgensen KK, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. 2021. PMID: 33944876. doi:10.1001/jama.2021.4172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。